Enhanced Medium Chain Triglyceride Compositions for Brain Energy Deficiency Conditions
Legal Citation
Summary of the Inventive Concept
This inventive concept relates to novel medium chain triglyceride compositions optimized for rapid ketone production, enhanced cognitive function, and improved brain energy metabolism in individuals with brain energy deficiency conditions or neurological diseases.
Background and Problem Solved
The original patent disclosed medium chain triglyceride compositions for treating brain energy deficiency conditions, but had limitations in terms of ketone production, cognitive function, and bioavailability. The present inventive concept addresses these limitations by introducing optimized ratios of MCT-C8 to MCT-C10, controlled-release dosage forms, tailored emulsifiers, and customizable ratios based on individual metabolic profiles.
Detailed Description of the Inventive Concept
The new claims introduce a system for treating brain energy deficiency conditions comprising a medium-chain triglyceride composition with an optimized ratio of MCT-C8 to MCT-C10 for rapid ketone production. This composition is administered in a controlled-release dosage form to provide a sustained energy boost to the brain. Additionally, a method for enhancing cognitive function in individuals with neurological conditions is disclosed, comprising administering a MCT composition with a tailored ratio of MCT-C8 to MCT-C10 to promote increased C10 fatty acid production and absorption. A novel emulsifier is also introduced to enhance bioavailability and absorption of the MCTs, thereby increasing ketone production and energy delivery to the brain.
Novelty and Inventive Step
The new claims introduce several novel and non-obvious features, including the optimized ratio of MCT-C8 to MCT-C10 for rapid ketone production, the controlled-release dosage form, the tailored emulsifier, and the customizable ratio based on individual metabolic profiles. These features provide a significant improvement over the original patent and demonstrate an inventive step.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept include using different ratios of MCT-C8 to MCT-C10, varying the type and amount of emulsifier, and incorporating additional ingredients to enhance cognitive function or neuroprotective effects. Variations of the inventive concept may also include different dosage forms, such as capsules, tablets, or liquids.
Potential Commercial Applications and Market
The enhanced medium chain triglyceride compositions have significant commercial potential in the nutraceutical and pharmaceutical industries, particularly in the areas of brain health, cognitive function, and neurological diseases. The target market includes individuals with brain energy deficiency conditions, such as Alzheimer's disease, Parkinson's disease, and epilepsy, as well as those seeking to improve cognitive function and overall brain health.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical and nutritional compositions, specifically medium-chain triglyceride (MCT) formulations for neurological and metabolic treatments, with expertise in lipid chemistry, metabolic engineering, and drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biochemistry, pharmaceutical sciences, or chemical engineering, having knowledge of lipid metabolism, ketone production, and neurological treatment strategies, with access to scientific literature and standard pharmaceutical formulation techniques
Obviousness Rationale
A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about MCT compositions for brain energy metabolism. The proposed modifications involve standard pharmaceutical formulation techniques like controlled-release dosing, emulsifier optimization, and metabolic profile customization, which are well-established approaches in nutritional and pharmaceutical product development. The fundamental scientific principles underlying MCT-based brain energy support remain consistent between the source patent and the PTD.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,527 |
|---|---|
| Title | Medium chain triglyceride compositions |
| Assignee(s) | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |